title: VAD therapy 20/20: moving beyond the myopic view of a nascent therapy.
abstract: The past five years have seen remarkable growth in the use of durable, continuous flow left ventricular assist devices (LVAD) with associated improvements in mortality, quality of life, functionality and end-organ function. To sustain the growth of this important therapy, the LVAD community must now address key issues focused around the costs of LVAD care, refined patient selection, and reducing complications associated with this therapy. In this perspective piece, we discuss many of these issues.
authors.affiliation: 1 Duke Clinical Research Institute, 2 Department of Medicine, 3 Division of Cardiothoracic Surgery, Duke University School of Medicine, Durham, NC 27715, USA.
authors.forename: Adam D
authors.initials: AD
authors.lastname: DeVore
authors.affiliation: 1 Duke Clinical Research Institute, 2 Department of Medicine, 3 Division of Cardiothoracic Surgery, Duke University School of Medicine, Durham, NC 27715, USA.
authors.forename: Carmelo A
authors.initials: CA
authors.lastname: Milano
authors.affiliation: 1 Duke Clinical Research Institute, 2 Department of Medicine, 3 Division of Cardiothoracic Surgery, Duke University School of Medicine, Durham, NC 27715, USA.
authors.forename: Joseph G
authors.initials: JG
authors.lastname: Rogers
keywords: Mechanical support; advanced heart failure; ventricular assist devices (VAD)